Endotrophin as a biomarker and mediator in cardiovascular-kidney-metabolic syndrome: current insights and remaining questions.
Por:
Genovese F, Karsdal M, Devos H, Bager C, Nuñez J and Bayes-Genis A
Publicada:
1 feb 2026
Ahead of Print:
9 dic 2025
Resumen:
Endotrophin, a biologically active fragment derived from the a3 chain of collagen type VI, has emerged as both a risk biomarker and a potential pathogenic factor in cardiovascular-kidney-metabolic (CKM) syndrome. Over the past decade, research has shed light on its role in various noncommunicable diseases, emphasizing its signaling properties and diagnostic potential. Despite these advances, significant gaps remain in our understanding of how endotrophin contributes to CKM pathophysiology and whether targeting it therapeutically could modify disease progression. This narrative review synthesizes current evidence on endotrophin biological functions and clinical associations, drawing from both experimental and clinical studies. In addition, it identifies critical areas where further investigation is required, including the molecular mechanisms linking endotrophin to CKM-related tissue dysfunction and its causal role in disease development. By mapping current knowledge and highlighting research priorities, this review aims to advance the field toward a more complete understanding of endotrophin as a potential therapeutic target.
Filiaciones:
Genovese F:
Nordic Bioscience A/S, Herlev, Denmark
Karsdal M:
Nordic Bioscience A/S, Herlev, Denmark
Devos H:
Nordic Bioscience A/S, Herlev, Denmark
Bager C:
Nordic Bioscience A/S, Herlev, Denmark
Nuñez J:
Cardiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
INCLIVA, CIBER Cardiovascular, Universidad de Valencia, Valencia, Spain
:
INCLIVA, CIBER Cardiovascular, Universidad de Valencia, Valencia, Spain
Heart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain
Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain
hybrid
|